North American Pulmonary drug delivery devices Market Research Report

The North American pulmonary drug delivery devices market is mainly driven by patent cliffs, increased incidence of chronic diseases, increasing competition, improving patient compliance, reformulation and repositioning of drugs using advanced oral delivery systems, and huge investments made by big pharmaceutical companies on in-house capabilities-for the development of oral drug delivery technologies. It was valued at $13.80 billion in 2013, and expected to grow at a CAGR of 11.80% to reach $24.00 billion by 2018.

A significant trend in the usage of pulmonary devices is a shift from the traditionally used nebulizers to pressurized MDIs (pMDIs), and in the recent years, from pMDIs to DPIs. While pMDIs currently retain their position with the largest market size, DPIs are expected to overtake the market share of pMDIs. The market has also become more patient-centric with patient-friendly features such as dose counters and devices requiring low inspiratory efforts. Application of pulmonary delivery for non-respiratory therapies is expected to be a huge opportunity in this market.

The North American market segmentation in this report comprises of the United States and Canada. The key drivers for the pulmonary drug delivery market in North America are the robust pharmaceutical industry, large number of pharmaceutical companies and drug delivery technology providers, and the increasing number of collaborations and partnerships between technology providers and pharmaceutical companies. In addition, an increased demand for self-administration & home healthcare devices and increasing applications of inhalers, transdermal patches, and transmucosal systems for chronic disease areas such as migraine, diabetes, cancer pain, and asthma have boosted the growth of this market.

The report also provides an extensive competitive landscaping of companies operating in the pulmonary drug delivery devices market. The main companies operating in the market are GlaxoSmithKline Pharmaceuticals Limited (GSK), Boehringer Ingelheim GmbH, and Astra Zeneca.

Segment and country-specific company shares, news & deals, M&A, segment-specific pipeline products, product approvals, and product recalls of the major companies have been detailed in this report.

Customization Options

Along with the market data, you can also customize the MMM assessments that meet your company’s specific needs. Customize to get comprehensive industry standard and deep-dive analysis of the following parameters:

Product Analysis

Usage pattern (in-depth trend analysis) of products (segment-wise)

Product matrix which gives a detailed comparison of the product portfolio of each company, mapped at country and sub-segment level

End-user Adoption rate analysis of the products (segment-wise and country-wise)

We will customize the research for you, in case the report listed above does not
meet with your exact requirements. Our custom research will comprehensively cover
the business information you require to help you arrive at strategic and profitable
business decisions.

North American Drug Delivery Devices Market
The North American Drug Delivery Devices Market was valued at $16 billion in 2013 and expected to be $110 billion by 2018, growing at a CAGR of 8.9%. The report “North American Drug Delivery Devices Market Forecast, 2012-2018“analyzes the market of Drug Delivery Devices by 9 technologies such as oral, transdermal, respiratory, injectable, implantable, transmucosal, nasal, ocular and topical drug delivery devices. The main companies operating in Drug Delivery Devices market and extensively covered in this report are SkyePharma Plc (U.K.), Ypsomed Holding AG (Switzerland), and GSK (U.K.).

Upcoming

European Drug Delivery Devices Market
The European Drug Delivery Devices Market was valued at $45 billion in 2013 and expected to be $63 billion by 2018, growing at a CAGR of 8.3%. The report “European Drug Delivery Devices Market Forecast, 2012-2018“analyzes the market of Drug Delivery Devices by 9 technologies such as oral, transdermal, respiratory, injectable, implantable, transmucosal, nasal, ocular and topical drug delivery devices. The main companies operating in Drug Delivery Devices market and extensively covered in this report are SkyePharma Plc (U.K.), Ypsomed Holding AG (Switzerland), and GSK (U.K.).